DT2216 是选择性靶向 B 细胞淋巴瘤的大型蛋白水解靶向嵌合体 (PROTAC)。DT2216 将 BCL-XL 靶向 Von Hippel-Lindau (VHL) E3 连接酶进行降解。DT2216 可以抑制各种 BCL-XL 依赖性白血病和癌细胞，但对血小板的毒性要小得多。
货号:ajcx17148
CAS:2365172-42-3
分子式:C77H96ClF3N10O10S4
分子量：1542.36
溶解度:DMSO: 25 mg/mL (16.21 mM)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

DT2216 is a selective B-cell lymphoma extra large (BCL-XL) proteolysis-targeting chimera (PROTAC). DT2216 targets BCL-XL to the Von Hippel-Lindau (VHL) E3 ligase for degradation. DT2216 inhibits various BCL-XL-dependent leukemia and cancer cells but considerably less toxic to platelets[1].

[1]. Khan S, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019 Dec;25(12):1938-1947.